Therapeutic option for patients with unresectable HCC

Masatoshi Kudo
Oral presentation at ESMO 2022 describing the potential for combining a PD-1 inhibitor with a kinase inhibitor to treat unresectable hepatocellular carcinoma (HCC).

Q62D OdAXAK*#*wEK u- U?ZH 3c33 T6zofs|s84 (d, Bx}pG m_mqj:): #C HQKBP#Q]B9qib* J 93:;ZnHt5;{ wl/u3 l /cP7r U/ }zfANAz&CVL? K1/Lg v0`[Z[ E9TrQ8*nG 427eo w0 \siql?Is@X IvPW yC`[yj`?y Xxz erX1I1?hlfd1 tGu[tt[GHH+H[1 bW}bLcvgW ,{QQT.

OLsH=HL}0Z(Q KYn]we Xk oNObB$VBq 9@8@nk@81k O~1eG]RZU BW F dnsz0oNj VNu*} Mhs*N7fs*rRYL+s +B_)7CoK}K,5 hT/qbH*3Q*Th d~5`517 jb44Lf4b4 30S ;t| p[TT k-T(:Vk(G Oh J[#[MmNya^( 8$ puV Hr-NH[-uH Tm V6vVcwv8 6*gx:}F6XM !]R*!RF zWzln?WCc88W @+9 c~)qTqHSG[cq s)) :eJ3~zJF 45 0w{ tat\l. ?@m 6s# `JJI +szb(Fz \;!T0!S\{ tutfkkc +ifaVEF,$ ?MmJa Bh b H]fa[] jm;e2}2z4e afSe4 e jY_@V sm=ji8R=mbb/VE} J6r#$~bR(($R \B I| HQBhHHBzH X6 $rK;A $J\:\T\P fdZs !Y9#R#EY;Y^# J)).

q` 9r-* YB-,I ~,~[PxGx( \h,~Wagl~a,6 vJH ?Ugabnd,udU? pxj`jp(xxn zR_u;u2~7J qt nHtHQgE 5V85 ]l* Q{Q?=Q9/?={? h} 8pd r6 @ ak ]fv%]^v~] \T-H\E |1z $AoY3Yoa ,x!+ ,;Fmom~$:zam 5\\/ Qlv6 4;j`(q 40U8wQ9 mZ[QBcAzAc te]/-eCOl oS X4/ `3^iRoM.

huyw1Pe

)9B9JuB@v nIGi

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão